Brief: Anavex Life Sciences Announces Positive Precision Medicine Results From Up To 4-Years Of Oral Blarcamesine Treatment In Phase Iib/Iii Open-Label Extension Trial In Early Alzheimer’S Disease
31/07/2025 13:15
July 31 (Reuters) - Anavex Life Sciences Corp AVXL.O: ANAVEX LIFE SCIENCES ANNOUNCES POSITIVE PRECISION MEDICINE RESULTS FROM UP TO 4-YEARS OF ORAL BLARCAMESINE TREATMENT IN PHASE IIB/III OPEN-LABEL EXTENSION TRIAL IN EARLY ALZHEIMER’S DISEASE Source text: ID:nGNX3kJ40z Further company coverage: AVXL.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Anavex Life Sciences
See all newsBrief: Anavex Provides Corporate Update, Announces Completion Of Clinical Conduct Of Adme And Ddi Clinical Studies
Brief: Anavex Receives FDA Clearance Of Its Ind Application For Blarcamesine In Fragile X Syndrome
Brief: Glass Lewis Recommends Anavex Stockholders To Vote For PVG’s Director Nominees
Brief: PVG Calls For Replacing Anavex Board, Hiring "Experienced" CEO
Brief: Pvg Asset Management- Nominates Six Director Candidates For Anavex Board